Piscataway, NJ, June 6, 2023–Camber Pharmaceuticals is pleased to announce the addition of Mexiletine Hydrochloride Capsules, USP to its current portfolio.
Mexiletine Hydrochloride Capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
Mexiletine Hydrochloride Capsules, USP are available in 150, 200 and 250 mg strengths in 100 count bottles.
To find out more about Mexiletine Hydrochloride Capsules, USP please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
